MAJOR LATE TOXICITIES AFTER CONFORMAL RADIOTHERAPY FOR NASOPHARYNGEAL CARCINOMA-PATIENT- AND TREATMENT-RELATED RISK FACTORS

被引:104
作者
Lee, Anne W. M. [1 ]
Ng, W. T. [1 ]
Hung, W. M. [1 ]
Choi, C. W. [1 ]
Tung, Raymond [3 ]
Ling, Y. H. [1 ]
Cheng, Peter T. C. [1 ]
Yau, T. K. [1 ]
Chang, Amy T. Y. [1 ]
Leung, Samuel K. C. [2 ]
Lee, Michael C. H. [2 ]
Bentzen, Soren M. [4 ]
机构
[1] Pamela Youde Nethersole Eastern Hosp, Dept Clin Oncol, Chaiwan, Hong Kong, Peoples R China
[2] Pamela Youde Nethersole Eastern Hosp, Dept Med Phys, Chaiwan, Hong Kong, Peoples R China
[3] Hong Kong Canc Fund, Hong Kong, Hong Kong, Peoples R China
[4] Univ Wisconsin, Dept Human Oncol, Sch Med & Publ Hlth, Madison, WI USA
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 2009年 / 73卷 / 04期
关键词
Nasopharyngeal carcinoma; Late toxicity; Concurrent chemotherapy; Radiation boost; SENSORINEURAL HEARING-LOSS; ACCELERATED FRACTIONATION; CONCURRENT CHEMORADIOTHERAPY; THERAPEUTIC GAIN; NORMAL TISSUE; TUMOR-CONTROL; LOCAL-CONTROL; CHEMOTHERAPY; CANCER; RADIATION;
D O I
10.1016/j.ijrobp.2008.05.023
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To retrospectively analyze the factors affecting late toxicity for nasopharyngeal carcinoma. Methods and Materials: Between 1998 and 2003, 422 patients were treated with a conformal technique with 2-Gy daily-fractions to a total dose of 70 Gy. Conventional fractionation (5 fractions weekly) was used in 232 patients and accelerated fractionation (6 fractions weekly) in 190 patients. One hundred seventy-one patients were treated with the basic radiotherapy course alone (Group 1), 55 patients had an additional boost of 5 Gy in 2 fractions (Group 2), and 196 patients underwent concurrent cisplatin-based chemotherapy (Group 3). Results: The 5-year overall toxicity rate was significantly greater in Group 3 than in Group 1 (37% vs. 27%, p 0.009). Although the overall rate in Group 2 was not elevated (28% vs. 27%, p = 0.697), a significant increase in temporal lobe necrosis was observed (4.8% vs. 0%,p = 0.015). Multivariate analyses showed that age and concurrent chemotherapy were significant factors. The hazard ratio of overall toxicity attributed to chemotherapy was 1.99 (95% confidence interval, 1.32-2.99,p = 0.001). The mean radiation dose to the cochlea was another significant factor affecting deafness, with a hazard ratio of 1.03 (95 % confidence interval, 1.01-1.05, p = 0.005) per 1-Gy increase. The cochlea that received >50 Gy had a significantly greater deaf rate (Group 1, 18% vs. 7%; and Group 3, 22% vs. 14%). Conclusion: The therapeutic margin for nasopharyngeal carcinoma is extremely narrow, and a significant increase in brain necrosis could result from dose escalation. The significant factors affecting the risk of dearness included age, concurrent chemoradiotherapy, and greater radiation dose to the cochlea. (C) 2009 Elsevier Inc.
引用
收藏
页码:1121 / 1128
页数:8
相关论文
共 25 条
[1]   Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized intergroup study 0099 [J].
Al-Sarraf, M ;
LeBlanc, M ;
Giri, PGS ;
Fu, KK ;
Cooper, J ;
Vuong, T ;
Forastiere, AA ;
Adams, G ;
Sakr, WA ;
Schuller, DE ;
Ensley, JF .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (04) :1310-1317
[2]  
[Anonymous], 2003, COMM TERM CRIT ADV E
[3]  
[Anonymous], 1997, J CLIN PATHOL
[4]   Chemotherapy in locally advanced nasopharyngeal carcinoma: An individual patient data meta-analysis of eight randomized trials and 1753 patients [J].
Baujat, B ;
Audry, W ;
Bourhis, J ;
Chan, ATC ;
Onat, H ;
Chua, DTT ;
Kwong, DLW ;
al-Sarraf, M ;
Chi, KH ;
Hareyama, M ;
Leung, SF ;
Thephamongkhol, K ;
Pignon, JP .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 64 (01) :47-56
[5]   Ototoxicity after radiotherapy for head and neck tumors [J].
Bhandare, Niranjan ;
Antonelli, Patrick J. ;
Morris, Christopher G. ;
Malayapa, Robert S. ;
Mendenhall, William M. .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2007, 67 (02) :469-479
[6]   PATTERNS OF HEARING-LOSS RESULTING FROM CISPLATINUM THERAPY [J].
BLAKLEY, BW ;
MYERS, SF .
OTOLARYNGOLOGY-HEAD AND NECK SURGERY, 1993, 109 (03) :385-391
[7]   Experience in fractionated stereotactic body radiation therapy boost for newly diagnosed nasopharyngeal carcinoma [J].
Chen, Helen H. W. ;
Tsai, Sen-Tien ;
Wang, Mei-Shu ;
Wu, Yuan-Hua ;
Hsueh, Wei-Ting ;
Yang, Ming-Wei ;
Yeh, I-Chun ;
Lin, Jin-Ching .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2006, 66 (05) :1408-1414
[8]  
COX DR, 1972, J R STAT SOC B, V34, P187
[9]   TOXICITY CRITERIA OF THE RADIATION-THERAPY ONCOLOGY GROUP (RTOG) AND THE EUROPEAN-ORGANIZATION-FOR-RESEARCH-AND-TREATMENT-OF-CANCER (EORTC) [J].
COX, JD ;
STETZ, J ;
PAJAK, TF .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (05) :1341-1346
[10]   TOLERANCE OF NORMAL TISSUE TO THERAPEUTIC IRRADIATION [J].
EMAMI, B ;
LYMAN, J ;
BROWN, A ;
COIA, L ;
GOITEIN, M ;
MUNZENRIDER, JE ;
SHANK, B ;
SOLIN, LJ ;
WESSON, M .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1991, 21 (01) :109-122